NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

$40.93

+3.28 (+8.71 %)

(As of 01/17/2020 07:42 AM ET)

Add

Compare

Today's Range

$37.94

Now: $40.93▼

$41.17

50-Day Range

$28.01

MA: $34.55▼

$40.93

52-Week Range

$6.16

Now: $40.93▼

$41.17

Volume1.30 million shs

Average Volume743,200 shs

Market Capitalization$2.38 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.28

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:CCXI

Previous Symbol

CUSIP16383L10

CIK1340652

Webhttp://www.chemocentryx.com/

Phone650-210-2900

Debt

Debt-to-Equity Ratio0.32

Current Ratio3.12

Quick Ratio3.12

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$42.88 million

Price / Sales55.41

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.29 per share

Price / Book141.14

Profitability

EPS (Most Recent Fiscal Year)($0.76)

Net Income$-37,970,000.00

Net Margins-143.30%

Return on Equity-88.76%

Return on Assets-23.42%

Miscellaneous

Employees76

Outstanding Shares58,048,000

Market Cap$2.38 billion

Next Earnings Date3/9/2020 (Estimated)

OptionableOptionable

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

THIS Marijuana SuperGreenhouse Is About To Change the Weed Market (Ad)

Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) issued its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.06. The biopharmaceutical company earned $10.58 million during the quarter, compared to analyst estimates of $7.83 million. ChemoCentryx had a negative return on equity of 88.76% and a negative net margin of 143.30%. View ChemoCentryx's Earnings History.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

What price target have analysts set for CCXI?

7 Wall Street analysts have issued 1 year target prices for ChemoCentryx's shares. Their forecasts range from $22.00 to $56.00. On average, they anticipate ChemoCentryx's stock price to reach $41.33 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price. View Analyst Price Targets for ChemoCentryx.

What is the consensus analysts' recommendation for ChemoCentryx?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:

1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (1/3/2020)
2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019)

Has ChemoCentryx been receiving favorable news coverage?

Press coverage about CCXI stock has been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ChemoCentryx earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for ChemoCentryx.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a drop in short interest in December. As of December 31st, there was short interest totalling 2,030,000 shares, a drop of 29.5% from the December 15th total of 2,880,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 1.7 days. Approximately 5.0% of the shares of the stock are short sold. View ChemoCentryx's Current Options Chain.

Who are some of ChemoCentryx's key competitors?

Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Arrowhead Pharmaceuticals (ARWR), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Opko Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN) and CBL & Associates Properties (CBL).

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:

Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
Dr. Rajinder Singh, Sr. VP of Research (Age 52)
Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $40.93.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $2.38 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is http://www.chemocentryx.com/.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]

MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		264 (Vote Outperform)
Underperform Votes:		252 (Vote Underperform)
Total Votes:		516

MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Dividend Stocks - Are They Right For You?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.